Sign in

Héctor A. Vaquera

@vaquerah-md.bsky.social
84 followers 52 following 10 posts

🇲🇽 Research fellow at Hematology Dept @uanl | Hematology. Lymphomas. Myeloma. HSCT.🩸🎗️

PostsRepliesMedia
Héctor A. Vaquera @vaquerah-md.bsky.social · 23/05/2025
Happy to share our latest publication For many in LMICs low-dose PD-1 blockers is the only way to afford this drugs and emergenig evidence suggests interesting things. Are we ready for more rigorous study of this intervention? ascopubs.org/doi/10.1200/...
ascopubs.org
ASCO Publications
110
Héctor A. Vaquera @vaquerah-md.bsky.social · 07/12/2024
Results from the AQUILA trial #ASH24 A few thoughts: - In absence of figures in uploaded abstracts, the n at risk table in the presentation is going to be important to pay attention to - How many of such progression events were SLiM? ash.confex.com/ash/2024/web...
ash.confex.com
Paper: Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
130
Reposted by Héctor A. Vaquera
James Wu | 吴简凡 MD @jamesfanwu.bsky.social · 07/12/2024
Hung out with fellow @ash-hematology.bsky.social HONORS Alumnus @vaquerah-md.bsky.social & meet his classmate Rubi at ASH-a-Palooza! Learned so much about medical training in Mexico from these two. Watch out for these two amazing trainees who are changing the world! #ASHTrainee #ASHKudos #ASH24
2101
Reposted by Héctor A. Vaquera
American Society of Hematology @ash.hematology.org · 06/12/2024
We are loving the bracelets at #ASH24!
0312
Héctor A. Vaquera @vaquerah-md.bsky.social · 06/12/2024
Ready to go! #ASH24
070
Héctor A. Vaquera @vaquerah-md.bsky.social · 05/12/2024
Badge ready, bags ready! See you tomorrow in #ASH24, looking forward to connect with other trainees tomorrow at ASH-a-Pallooza 🤩🩸
030
Héctor A. Vaquera @vaquerah-md.bsky.social · 05/12/2024
Finally time for #ASH24! Very excited to learn tons and connect with colleagues! Let's see whats new in #Lymphoma and #Myeloma 🙂‍↕️ Anyone open to chat about those topics and methods/stats, I would love it!
010
Reposted by Héctor A. Vaquera
Shematologist, MD @shematologist.medsky.social · 25/11/2024
Our study found that nearly 40% (!) of 12-21 yo females are iron deficient. tinyurl.com/FeJAMA But did you know that in addition to many physical symptoms, iron deficiency is associated with multiple mental health issues? A #medsky #bluetorial 🧵1/
tinyurl.com
Prevalence of Iron Deficiency and Iron-Deficiency Anemia in US Females Aged 12-21 Years, 2003-2020
This study examines prevalence of iron deficiency among females aged 12 to 21 years to inform future screening strategies for iron deficiency and iron-deficiency anemia.
57482165
Reposted by Héctor A. Vaquera
Nihar Desai MD, DM @nihardesai7.bsky.social · 21/11/2024
🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky
43611
Héctor A. Vaquera @vaquerah-md.bsky.social · 25/11/2024
Check out our new work in Annals of Hematology: ✅ 73% ORR ✅ 43% CR ⚠️ 61% Grade 1-2 AE ✅ No Grade 3-4 AE link.springer.com/article/10.1...
link.springer.com
Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory Hodgkin lymphoma - Annals of Hematology
Up to one-third of patients with classical Hodgkin lymphoma (cHL) are not responsive to first-line therapy or eventually relapse. Immune checkpoint inhibitors (ICIs) have been successfully employed to...
110